Clinical Trials Browser

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Phase 2 Not yet recruiting

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT07018570 2025-08-26

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

26 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT04069273 2025-07-31

SEQUEL

Phase 2 Recruiting

58 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03664024 2024-08-22

KEYNOTE-782

Phase 2 Completed

118 enrolled 14 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT03997448 2024-02-20

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Phase 2 Terminated

3 enrolled 10 charts

Tumor-Agnostic

Adenocarcinoma

NCT02918162 2024-02-15

Perioperative Chemo and Pembrolizumab in Gastric Cancer

Phase 2 Completed

49 enrolled 10 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03488667 2023-05-19

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Phase 2 Active not recruiting

40 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

5 enrolled

Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2 Unknown

35 enrolled

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT02943603 2018-07-13

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Clinical Trials

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

DG-03

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Cabozantinib and Pembrolizumab in Metastatic Pancreas

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

SEQUEL

KEYNOTE-782

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Perioperative Chemo and Pembrolizumab in Gastric Cancer

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach